Glenmark Launches Generic Acne Treatment in US
Glenmark Pharmaceuticals's US arm has launched a generic version of Clindamycin Phosphate foam, an antibiotic acne treatment. The drug is bioequivalent to Evoclin foam 1 percent and achieved annual sales of USD 5.8 million in 2024.
New Delhi, Feb 12 (PTI) Glenmark Pharmaceuticals Ltd on Wednesday said its US arm has launched the generic version of Clindamycin Phosphate foam, an antibiotic acne treatment medicine.
Glenmark Pharmaceuticals Inc., USA (Glenmark) announces the launch of Clindamycin Phosphate Foam 1 per cent, which is bioequivalent and therapeutically equivalent to the reference listed drug Evoclin foam 1 per cent of Mylan Pharmaceuticals Inc, the company said in a statement.
Citing IQVIA sales data for the 12-month period ending December 2024, the Evoclin foam 1 per cent market achieved annual sales of approximately USD 5.8 million, it added.
Glenmark Pharmaceuticals Inc., USA (Glenmark) announces the launch of Clindamycin Phosphate Foam 1 per cent, which is bioequivalent and therapeutically equivalent to the reference listed drug Evoclin foam 1 per cent of Mylan Pharmaceuticals Inc, the company said in a statement.
Citing IQVIA sales data for the 12-month period ending December 2024, the Evoclin foam 1 per cent market achieved annual sales of approximately USD 5.8 million, it added.
You May Like To Read
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- Vodafone Idea L
- 7.76 ( -1.02)
- 43574321
- Sunshine Capital
- 0.29 ( 0.00)
- 34602782
- Alok Industries Ltd.
- 22.02 (+ 5.92)
- 32345676
- Jaiprakash Power Ven
- 22.75 ( -4.25)
- 30858800
- Sattva Sukun Lifecar
- 0.79 ( -9.20)
- 20534098
MORE NEWS
© 2025 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback